Relay Therapeutics (RLAY) EBITDA (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of EBITDA data on file, last reported at -$73.5 million in Q1 2026.

• Quarterly EBITDA rose 3.38% year-over-year to -$73.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$272.2 million (up 18.06% YoY) and the FY2025 annual result came in at -$274.8 million, up 18.83% from the prior year.
• EBITDA declined to -$73.5 million in Q1 2026 per RLAY's latest filing, from -$54.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$54.6 million in Q4 2025 and bottomed at -$98.8 million in Q2 2023.
• The 5-year median for EBITDA is -$79.5 million (2022), against an average of -$77.5 million.
• Peak annual rise in EBITDA reached 58.92% in 2022, while the deepest fall reached 66.15% in 2022.
• Tracing RLAY's EBITDA over 5 years: stood at -$64.5 million in 2022, then dropped by 24.44% to -$80.3 million in 2023, then grew by 1.0% to -$79.5 million in 2024, then soared by 31.26% to -$54.6 million in 2025, then sank by 34.42% to -$73.5 million in 2026.
• Per Business Quant, the three latest RLAY EBITDA figures stand at -$73.5 million (Q1 2026), -$54.6 million (Q4 2025), and -$73.5 million (Q3 2025).

Peer Comparison